跳至主要内容
临床试验/NCT02426099
NCT02426099已完成4 期

Prevalence and Treatment of Resistant Hypertension in Diabetic Patients in Yaounde

Sobngwi Eugene1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2011年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
17
试验地点
1
主要终点
Efficacy (Blood pressure reduction)

研究概览

简要总结

This is a four-week randomized controlled single blinded trial of subjects presenting with resistant hypertension in a specialized diabetes care unit of Cameroon. They are randomly assigned using the method of blocks to treatment with a daily 25mg of spironolactone or to routine intensification of antihypertensive regimen , all added to previous regimen with unchanged diet. Visits are scheduled at the start of the treatment, at weeks two and four following add-on therapy initiation. The primary outcome is change in office and self-measurement blood pressure recorded at each visit, and secondary outcomes are variations in serum potassium, sodium, and creatinine levels.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
21 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Resistant hypertension
  • Diabetes mellitus

排除标准

  • T2DM with overt acute/chronic complications,
  • serum potassium ≥ 5.5 mmol/l,
  • estimated Glomerular Filtration Rate (eGFR) calculated using the Modification of Diet in Renal Disease formula ≤ 30 ml/min/1.73m² of body weight,
  • absolute contraindication to any of the drug regimen of the trial,
  • and current aldosterone antagonist treatment or cessation within the last 15 months

研究组 & 干预措施

Low dose Spironolactone

Experimental

Add-on low dose 25 mg Spironolactone to current hypertension treatment

干预措施: Low dose spironolactone (Drug)

Routine

Active Comparator

Routine intensification of anti hypertensive treatment based on existing guidelines

干预措施: Routine intensification of antihypertensive treatment (Other)

结局指标

主要结局

Efficacy (Blood pressure reduction)

时间窗: 4 weeks

Blood pressure reduction

次要结局

  • Potassium (Change in serum potassium)(4 weeks)
  • Creatinine (Change in serum creatinine)(4 weeks)

研究者

发起方
Sobngwi Eugene
申办方类型
Other Gov
责任方
Sponsor Investigator
主要研究者

Sobngwi Eugene

Professor and Consultant Physician

Yaounde Central Hospital

研究点 (1)

Loading locations...

相似试验

Efficacy of Spironolactone in Cameroonian Diabetic... | 临床试验